CCK receptor antagonists in animal models of anxiety: Comparison between exploration tests, conflict procedures and a model based on defensive behaviours

Behavioural Pharmacology

Volumn 8, Issue 6-7, 1997, Pages 549-560

  Griebel, G ^a   Perrault, Gh ^a   Sanger, D J ^a  

^a SANOFI   (France)

Author keywords

Animal models; Anxiety; CCK antagonists; Conflict tests; Defensive behaviours; Exploration models; Lorglumide; LY 288513; Mouse; Panic; PD 135,158; Rat

Indexed keywords

CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DIAZEPAM; LORGLUMIDE; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; PD 135158;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONFLICT; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; EXPLORATORY BEHAVIOR; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PANIC; RAT;

EID: 0030834576     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-199711000-00013     Document Type: Article

References (52)

1. Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, Wisselink PG, Greiner M, Pierce MW and Pande AC (1995) A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology, 15, 428-434.
2. Belzung C, Pineau N, Beuzen A and Misslin R (1994) PD135158, a CCK-B antagonist, reduces 'state', but not 'trait' anxiety in mice. Pharmacology, Biochemistry and Behavior, 49, 433-436.
3. Bickerdike MJ, Marsden CA, Dourish CT and Fletcher A (1994) The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. European Journal of Pharmacology, 271, 403-411.
4. Blanchard DC, Blanchard RJ and Rodgers RJ (1991) Risk assessment and animal models of anxiety. In: Animal Models in Psychopharmacology. (Eds B Olivier, J Mos and JL Slangen), pp. 117-134. Birkhauser Verlag AG, Basel.
5. Bourin M, Malinge M, Vasar E and Bradwejn J (1996) Two faces of cholecystokinin: anxiety and schizophrenia. Fundamental Clinical Pharmacology, 10, 116-126.
6. Bradwejn J, Koszycki D, Couëtoux du Tertre A, Van Megen H, Den Boer J, Westenberg H and Annable L (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Archives of General Psychiatry, 51, 486-493.
7. Charrier D, Dangoumau L, Puech AJ, Hamon M and Thiebot MH (1995) Failure of CCK receptor ligands to modify anxiety related behavioural suppression in an operant conflict paradigm in rats. Psychopharmacology (Berlin), 121, 127-134.
8. Chopin P and Briley M (1993) The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharmacology (Berlin), 110, 409-414.
9. Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ and Woodruff GN (1991) Anxiolytic effects of CCK-B antagonists. Neuropeptides, 19 (Suppl), 65-73.
10. Dawson GR, Rupniak NMJ, Iversen SD, Curnow R, Tye S, Stanhope KJ and Tricklebank MD (1995) Lack of effect of CCKB receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology (Berlin), 121, 109-117.
11. Della-Fera MA and Baile CA (1979) Cholecystokinin octapeptide: continuous picomole injections into the cerebral ventricles of sheep suppress feeding. Science, 206, 471-473.
12. Derrien M, McCort-Tranchepain I, Ducos B, Roques BP and Durieux C (1994) Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacology, Biochemistry and Behavior, 49, 133-141.
13. B receptor antagonist CI-988 and diazepam in the four-plate test. Psychopharmacology (Berlin), 112, 452-454.
14. Griebel G, Blanchard DC, Jung A and Blanchard RJ (1995) A model of 'antipredator' defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behavioural Pharmacology, 6, 732-745.
15. Griebel G, Blanchard DC and Blanchard RJ (1996a) Predator-elicited flight responses in Swiss-Webster an experimental model of panic attacks. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 20, 185-205.
16. 2A receptor antagonist S21357. Pharmacology, Biochemistry and Behavior, 54, 509-516.
17. Griebel G, Perrault G and Sanger DJ (1997a) Behavioural profiles of the reversible monoamine-oxydase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Psychopharmacology (Berlin) 131, 180-186.
18. Griebel G, Rodgers RJ, Perrault G and Sanger DJ (1997b) Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacology, Biochemistry and Behavior (in press).
19. Griebel G, Sanger DJ and Perrault G (1996c) The Mouse Defense Test Battery: evaluation of the effects of non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Behavioural Pharmacology, 7, 560-572.
20. Griebel G, Sanger DJ and Perrault G (1996d) Further evidence for differences between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands in murine models of 'state' and 'trait' anxiety. Neuropharmacology, 35, 1081-1091.
21. Griebel G, Sanger DJ and Perrault G (1996e) The use of the rat elevated plus-maze to discriminate between non-selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Psychopharmacology (Berlin), 124, 245-254.
22. Griebel G, Sanger DJ and Perrault G (1997c) Genetic differences in the mouse defense test battery. Aggressive Behavior, 23, 19-31.
23. Harro J and Vasar E (1991) Cholecystokinin-induced anxiety: how is it reflected in studies on exploratory behaviour? Neuroscience and Biobehavioral Reviews, 15, 473-477.
24. Harro J, Oreland L, Vasar E and Bradwejn J (1995) Impaired exploratory behaviour after DSP-4 treatment in rats: implications for the increased anxiety after noradrenergic denervation. European Neuropsychopharmacology, 5, 447-455 (abstract).
25. Helton DR, Berger JE, Czachura JF, Rasmussen K and Kallman MJ (1996) Central nervous system characterization of the new cholecystokinin, antagonist LY288513. Pharmacology, Biochemistry and Behavior, 53, 493-502.
26. Hendrie CA, Neill JC, Shepherd JK and Dourish CT (1993) The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiology and Behavior, 54, 689-693.
27. Hinks GL, Brown P, Field M, Poat JA and Hughes J (1996) The anxiolytics CI-988 and chlordiazepoxide fail to reduce immediate early gene mRNA stimulation following exposure to the rat-elevated X-maze. European Journal of Pharmacology, 312, 153-161.
28. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD and Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proceedings of the National Academy of Sciences (United States of America), 87, 6728-6732.
29. Izumi T, Inoue T, Tsuchiya K, Hashimoto S, Ohmori T and Koyama T (1996) Effect of the selective CCKB receptor antagonist LY288513 on conditioned fear stress in rats. European Journal of Pharmacology, 300, 25-31.
30. Jenck F, Martin JR and Moreau JL (1996) Behavioral effects of CCKB receptor ligands in a validated simulation of panic anxiety in rats. European Neuropsychopharmacology, 6, 291-298.
31. B) receptor ligands in the elevated plus-maze test of anxiety in mice. Psychopharmacology (Berlin), 124, 355-364.
32. B antagonist, L-365,260, attenuates fear-potentiated startle. Peptides, 16, 1313-1315.
33. B antagonist, in panic disorder. Biological Psychiatry, 37, 462-466.
34. Lines C, Challenor J and Traub M (1995) Cholecystokinin and anxiety in normal volunteers: an investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype B antagonist L-365,260. British Journal of Clinical Pharmacology, 39, 235-242.
35. Liu H, Chandler S, Beitz AJ, Shipley MT and Behbehani MM (1994) Characterization of the effect of cholecystokinin (CCK) on neurons in the periaqueductal gray of the rat: immunocytochemical and in-vivo and in-vitro electrophysiological studies. Brain Research, 642, 83-94.
36. Matto V, Harro J and Allikmets L (1996) The effects of cholecystokinin A and B receptor antagonists, devazepide and L 365260, on citalopram-induced decrease of exploratory behaviour in rat. Journal of Physiology and Pharmacology, 47, 661-669.
37. Misslin R, Belzung C and Vogel E (1989) Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behavioural Processes, 8, 119-132.
38. Molewijk HE, Hartog K, Vanderpoel AM, Mos J and Olivier B (1996) Reduction of guinea pig pup isolation calls by anxiolytic and antidepressant drugs. Psychopharmacology (Berlin), 128, 31-38.
39. Panerai AE, Rovati LC, Bianchi M, Bareggi SR and Mantegazza P (1987) Effect of a cholecystokinin antagonist on some effects of diazepam. Neuropharmacology, 26, 1285-1287.
40. Pellow S, Chopin P, File SE and Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. Journal of Neuroscience Methods, 14, 149-167.
41. Popoli P, Reggio R, Pezzola A and Decarolis AS (1995) The stimulation of cholecystokinin receptors in the rostral nucleus accumbens significantly antagonizes the EEG and behavioural effects induced by phenecyclidine in rats. Psychopharmacology (Berlin), 120, 156-161.
42. Powell KR and Barrett JE (1991) Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on the punished responding of squirrel monkeys. Neuropeptides, 19 (Suppl), 75-78.
43. Rataud J, Darche F, Piot O, Stutzmann JM, Bohme GA and Blanchard JC (1991) 'Anxiolytic' effect of CCK-antagonists on plus-maze behavior in mice. Brain Research, 548, 315-317.
44. Rex A, Fink H and Marsden CA (1994) Effects of BOC-CCK-4 and L 365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus-maze. Neuropharmacology, 33, 559-565.
45. Rodgers RJ and Cole JC (1994) The elevated plus-maze: pharmacology, methodology and ethology. In: Ethology and Psychopharmacology. (Eds SJ Cooper and CA Hendrie), pp. 9-44. John Wiley and Sons Ltd, Chichester.
46. Sanger DJ (1995) The behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue. Behavioural Pharmacology, 6, 116-126.
47. Singh L, Field MJ, Hughes J, Menzies R, Oles RJ, Vass CA and Woodruff GN (1991) The behavioural properties of CI-988, a selective cholecystokinin-B receptor antagonist. British Journal of Pharmacology, 104, 239-245.
48. Van Megen HJGM, Westenberg HGM, Den Boer JA, Haigh JRM and Traub M (1994) Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology (Berlin), 114, 449-455.
49. Van Megen HJGM, Westenberg HGM, Den Boer JA and Kahn RS (1996) Cholecystokinin in anxiety. European Neuropsychopharmacology, 6, 263-280.
50. Vasar E, Lang A, Harro J, Bourin M and Bradwejn J (1994) Evidence for potentiation by CCK antagonists of the effect of cholecystokinin octapeptide in the elevated plus-maze. Neuropharmacology, 33, 729-735.
51. Vogel JR, Beer B and Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia, 21, 1-7.
52. Woodruff GN and Hughes J (1991) Cholescystokinin antagonists. Annual Reviews in Pharmacology and Toxicology, 31, 469-501.